Regular Article
Suppression of C8161 Melanoma Metastatic Ability by Chromosome 6 Induces Differentiation-Associated Tyrosinase and Decreases Proliferation on Adhesion-Restrictive Substrates Mediated by Overexpression of p21WAF1 and Down-Regulation of bcl-2 and Cyclin D3

https://doi.org/10.1006/bbrc.2001.4330Get rights and content

Abstract

Metastatic tumors grow under conditions that restrict proliferation of non-metastatic, more differentiated cells. To investigate this prediction, we developed a simple adhesion-restrictive assay which allows proliferation of human metastatic C8161 melanoma, but prevents growth of neo 6.3/C8161 cells in which metastasis is suppressed by introduction of neo-tagged chromosome 6. We show that tyrosinase, a key enzyme in melanocytic cell differentiation, and expression of chromosome 6-encoded cell cycle modulators like p21WAF1 and cyclin D3 is selectively increased in C8161 tumors in which metastasisis is suppressed by chromosome 6. In the latter cells, growth arrest evidenced only under adhesion-restrictive conditions correlated with down-regulation of cyclin D3 and anti-apoptotic bcl-2. No comparable growth arrest or down-regulation was detected under comparable conditions in metastatic cells, which showed activation of invasion-associated MMP-9 92 kDa gelatinase B. Our data suggests that the metastasis-suppressing effects of chromosome 6 involving increased differentiation-associated tyrosinase and growth arrest on adhesion-restrictive substrates; are partly mediated by modulation of growth regulators, like p21WAF1 and cyclin D3.

References (20)

  • S.M. Frisch et al.

    Integrins and anoikis

    Curr. Opin. Cell Biol.

    (1997)
  • G. Scott et al.

    Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism

    J. Invest. Dermatol.

    (1997)
  • M. Rieber et al.

    Differential gene expression associated with suppression of melanoma cell spreading and proliferation on adhesion-restrictive substrates

    Proc. Amer. Assoc. Cancer Res.

    (1999)
  • D.R. Welch et al.

    Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity

    Oncogene

    (1994)
  • D.R. Welch et al.

    Is p21WAF1 a Suppressor of malignant melanoma metastasis?

    Mol. Cell Differ.

    (1996)
  • H. Kuchiki et al.

    Detection of amplification of a chromosomal fragment at 6p21 including the cyclin D3 gene in a glioblastoma cell line by arbitrarily primed PCR

    Int. J. Cancer

    (2000)
  • M. Strasberg-Rieber et al.

    Specific tyrosinases associated with melanoma replicative senescence and melanogenesis

    Cancer Res.

    (1993)
  • J.R. MacDougall et al.

    The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cells

    Cancer Res.

    (1995)
  • Rieber, M., and Strasberg-Rieber, M.Induction of p53 without increase in p21WAF1 in betulinic acid-mediated cell death...
There are more references available in the full text version of this article.

Cited by (6)

  • Nitroprusside induces melanoma ferroptosis with serum supplementation and prolongs survival under serum depletion or hypoxia

    2020, Biochemical and Biophysical Research Communications
    Citation Excerpt :

    CoCl2 is reported to increase ROS [41], unlike another hypoxia mimetic deferoxamine known to bind iron, prevent hydroxyl radical production, and inhibit Fenton redox reactions [42]. Taken together, (Fig. S2,Summary), this report extends our prior findings that adaptation to a restrictive microenvironment [1,28] mediates melanoma tumor heterogeneity by promoting phenotypic selection. Our results also suggest that anti-oxidants and inhibitors of the MEK/ERK pathway [26,43] may have distinct roles in controlling tumor phenotypic switching from a milieu permissive for proliferation to another promoting a CSC-like of slowly proliferating tumor cells [44,45].

  • KISS1 metastasis suppression and emergent pathways

    2003, Clinical and Experimental Metastasis
1

To whom correspondence should be addressed. E-mail: [email protected].

View full text